ENDRA Life Sciences Inc. (NDRA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on May 27, 2026, by ENDRA Life Sciences Inc., a Delaware corporation. The filing primarily addresses the entry into a Material Definitive Agreement for a private placement offering and updates regarding the company's compliance with Nasdaq listing requirements.
Key Financial Metrics and Transaction Details
- Offering Proceeds: The Company expects to raise approximately $3.8 million in gross proceeds from the private placement.
- Securities Issued: The offering includes 578,387 shares of Common Stock (or Prefunded Warrants) and Common Warrants to purchase up to 1,156,774 shares.
- Purchase Price: Each share (or Prefunded Warrant) and accompanying Common Warrant were sold at a combined price of $6.57 per share.
- Warrant Terms: Common Warrants have an exercise price of $6.57 and are exercisable for five years following the removal of exercisability restrictions. Prefunded Warrants are exercisable at $0.0001 per share.
- Stockholders' Equity: As of the filing date, the Company believes its stockholders' equity exceeds the $2.5 million Nasdaq minimum requirement, following a reported equity balance of $2,260,120 in its December 31, 2025, Form 10-K.
- Placement Agent Compensation: The Company will issue prefunded warrants to purchase 100,000 shares to Lucid Capital Markets, LLC as compensation.
Material Changes and Strategic Agreements
The filing details a Side Letter Agreement concurrent with the Securities Purchase Agreement. This agreement imposes specific conditions on the use of proceeds and potential repayment obligations:
- Segregated Funds: The Company must maintain a cash balance equal to or greater than the $3.8 million purchase price in a segregated bank account until a Potential Strategic Alternative closes or a Payment Obligation is made.
- Payment Obligation: If the Company decides not to pursue a definitive agreement with a specific strategic counterparty identified to the Purchaser, it must repay the Purchaser an amount equal to the Purchase Price less the fair market value of the securities purchased.
- Board Observer: The Purchaser has the right to designate one individual as a Board of Directors observer.
- Nasdaq Compliance: The Company previously received notice of non-compliance with the Minimum Stockholders' Equity Requirement in April 2026. The Company has requested a hearing and believes the current offering restores compliance.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements subject to significant risks and uncertainties. Key contingencies include:
- Strategic Alternative Risk: The likelihood of entering into a definitive agreement for a strategic alternative is uncertain. Failure to do so triggers the Payment Obligation under the Side Letter.
- Delisting Risk: While the Company believes it has regained compliance with Nasdaq rules, it is awaiting formal determination. There is a risk that the Nasdaq Hearings Panel may disagree with the Company's assessment.
- Financial Stability: The Company cites limited commercial experience, limited cash, and a history of losses as ongoing risks.
- Use of Proceeds: Net proceeds are intended for working capital and general corporate purposes, subject to the restrictions of the Side Letter Agreement.
Investor Verification Checklist
- Verify the formal determination from Nasdaq regarding the Company's compliance with the Minimum Stockholders' Equity Requirement.
- Confirm the status of any "Potential Strategic Alternative" discussions and the likelihood of a definitive agreement to avoid the Payment Obligation.
- Review the full text of the Side Letter Agreement (to be filed in the upcoming Form 10-Q) for specific exceptions to the repayment obligation and deposit control terms.
- Monitor the Company's cash balance in the segregated account to ensure it remains above the $3.8 million threshold as required.
- Assess the impact of the warrant overhang (1,156,774 shares) on future dilution if exercised.